Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United S...
Liquidia director Stephen M. Bloch sells 200,000 common shares for $17.87 million
Insider Decision: Stephen M Bloch Offloads $6.29M Worth Of Liquidia Stock
Major Insider Move Shakes Up Liquidia Technologies
Liquidia director Stephen M. Bloch reports disposal of 78,596 common shares worth $6.28 million
Analyst Raises Liquidia Price Target from $71 to $101 on Strengthened Legal Position and Yutrepia Adoption
The Wall Street Garage Sale: Real Winners, AI Hustlers, and a Crypto Funeral